Novartis Pharmaceutical Industry Fellowship Program 2024

Leadership | Tradition | Motivation
Development | Dedication

RUTGERS
Institute for Pharmaceutical Industry Fellowships

NOVARTIS

Message to Prospective Fellows

When I started my career as a Post-Doctoral fellow at Novartis, I was seeking a fulfilling career in an untraditional pharmacy setting. The Rutgers Pharmaceutical Industry Fellowship exposed me to unique opportunities, provided me with lifelong mentors, an incredible network of colleagues and allowed me to build the foundation for my career in the pharmaceutical industry. Through the years I have remained a strong advocate for the Rutgers Pharmaceutical Industry Fellowship as a key vehicle for accelerated professional development.

I can attest that the broad background possessed by a Pharm.D. graduate is highly valued in our industry – and certainly here at Novartis. Established in 1990, the Novartis Fellowship is one of the longest standing programs within the Rutgers family of fellowships with over 200 fellows completing the program, signifying its strength and longevity. Each year, we set out to find the “best and the brightest” among the nation’s pharmacy doctoral programs.

Novartis fellows consistently demonstrate the drive, self-motivation, and eagerness to learn and succeed within the various disciplines we offer, including early clinical development/translational medicine, clinical development, regulatory affairs, medical affairs, and commercial strategy/brand marketing.

I am enthusiastic about your interest in Novartis and wish you the best of luck during the challenging interview and application process.

Rob Kowalski, Pharm.D.

Chief People & Organization Officer
Novartis
Fellow 1993–1995

“The broad background possessed by a Pharm.D. graduate is highly valued in our industry – and certainly here at Novartis.”

Rob Kowalski was one of the first fellows in the original Sandoz fellowship program from 1993-1995. Rob attended the University of Wisconsin-Madison where he received both a Bachelor of Science in Pharmaceutical Sciences and a Doctorate in Pharmacy.

Contents

Who We Are.....4

Novartis Company Profile.....7

Novartis Fellowship Program Overview 9

Novartis Fellowship Program Leadership 11

Novartis Fellowship Program Fellows.....13

Novartis Fellowship Program Positions.....17

Commercial Fellowships 18

Global Development Fellowships 20

Medical Affairs Fellowships 26

Regulatory Affairs Fellowships 30

Novartis Fellowship Program Alumni 35

Rutgers Pharmaceutical Industry Fellowship Program.....39



Who We Are

Our Purpose

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

Our Culture	Our Values
Curious	Innovation
Inspired	Quality
Unbossed	Collaboration
Integrity	Performance
	Courage

Our Strategic Priorities



Who We Are

Our Company

Innovative Medicines

The Innovative Medicines Division has two commercial units: **Innovative Medicines US** and **Innovative Medicines International**. These units were created in April 2022 as part of our new, integrated organizational structure.



Research and Development (R&D)

The Novartis Institutes for Biomedical Research (NIBR)
is the innovation engine of Novartis, focused on discovering new medicines for diseases with unmet medical need.

Global Drug Development (GDD)
organization oversees the development of potential new medicines, running large clinical trials and steering the way to regulatory approval for general use in patients.

Who We Are

Our People

The greatest strength of Novartis is our people, whose diversity, energy and creativity are crucial to our success.

HEADCOUNT	NATIONALITIES	ANNUAL LEARNING HOURS PER EMPLOYEE	WOMEN IN MANAGEMENT
105,533	147	42.4	47%

Our Ethics

Novartis has adopted a single set of ethical principles that should be applied in daily decision-making by all Novartis associates.



Novartis Company Profile

Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. Our current portfolio includes more than 80 key marketed products, many of which are leaders in their respective therapeutic areas.

Novartis Pharmaceuticals Corporation is headquartered in East Hanover, New Jersey, which is approximately 40 miles west of New York City.

Novartis Gene Therapies is headquartered in Bannockburn, IL with another location in Deerfield, IL. We are dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Novartis Pipeline

Key Performance Indicators

2022 Annual Report

FINANCIAL

50.5 bn
Net sales (USD)

11.9 bn
Total free cash flow (USD)

16.7 bn
Core operating income (USD)

9.2 bn
Operating income (USD)

7.0 bn
Net income (USD)

INNOVATION

150 +
Projects in clinical development

10.0 bn
Research and development spend (USD)

SOCIAL

54.6 m
Patients reached through access programs

1.2 m
People reached through strategic innovative therapies

[1]In constant currencies and for continuing operations.

Our Products and Reach

We develop and produce innovative medicines to address patient needs in disease areas where our experience and knowledge have the potential to produce transformative treatments. We focus on five core therapeutic areas where there are high unmet patient needs:

- CARDIOVASCULAR
- SOLID TUMORS
- IMMUNOLOGY
- HEMATOLOGY
- NEUROSCIENCE

In addition, we have research and in-market programs in:

- OPHTHALMOLOGY
- RESPIRATORY

Through Novartis Gene Therapies, we are also exploring advanced therapy platforms such as genes and therapeutic viruses including Adeno-associated viruses (AAVs) in neuroscience, as well as potential treatments for Rett syndrome, a genetic form of amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia.

~140
COUNTRIES
where Novartis products are sold

236 m
PATIENTS
reached in total through Novartis Innovative Medicines

13 m
PATIENTS
reached through awareness events

Novartis Fellowship Program

Our Program

The first year of the fellowship is typically dedicated to one of the departments described in this brochure. In the second year, fellows have the option to remain in the same department or transfer to another group elsewhere within Novartis.

Specific fellowship opportunities within departments vary depending on the interests of prospective candidates as well as the opportunities within Novartis. In order to maximize their overall experience and to build a solid skill set, fellows may be presented with the opportunity to participate in special projects of interest. Fellows may also attend seminars and workshops designed to build professional skills such as time and project management, negotiation, and developing and delivering presentations. Opportunities to take internal training classes are also available. Fellows may be eligible to attend medical and professional conferences where they may present posters, participate in scientific sessions for continuing education credit, and network with colleagues.

Novartis fellows have the opportunity to participate in a three-month rotation either within or outside of Novartis. A broad range of opportunities are available, including clinical rotations at a university affiliated hospital, the Ernest Mario School of Pharmacy, government agencies such as the US Food and Drug Administration or the National Institutes of Health, or other external vendors. Such rotations are structured to allow fellows to broaden their experience.

Objectives

During the two-year program at Novartis, the fellow will:

1. Gain a comprehensive overview of key areas within the pharmaceutical industry through practical insights and experiences.
2. Expand clinical knowledge through participation in both industrial and academic programs.
3. Promote the role and value of a clinically trained pharmacist within the pharmaceutical industry.
4. Actively participate in specific areas of industry and academia through direct involvement in various projects and assignments.
5. Become highly marketable for employment opportunities within the pharmaceutical industry.

“Our name, derived from the Latin novae artes, means “new skills” and reflects our commitment to bringing new healthcare products to patients and physicians worldwide."

2023–2024 Novartis Fellowship Program Leadership

Directors

Angela Browne

Global Therapeutic Area Lead Regulatory Affairs, Early Development

Pharm.D., *B.S.*, Purdue University
Fellow 1999–2001

Kudsia Hafeez

Global Program Executive Director, Cardio-Renal-Metabolic

Pharm.D., Purdue University
Fellow 2001–2003

Fellowship Coordinator

Yuri Fiestas

Administrative Assistant

The Novartis Fellowship Program Leadership Team is comprised primarily of past fellows that work in partnership with preceptors to champion the fellowship experience. The Novartis group leaders are additional mentors that provide support, guidance and background for the fellows to maximize their experience at Novartis.

2023–2024 Novartis Fellowship Program Leadership

Group Leaders

Brian Manning

Senior Clinical Development Director, Cardio-Renal-Metabolic

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2009-2011

Christopher McBurney

Hematology Global TA Head
Global Product Strategy & Capabilities

Pharm.D., University of Toledo

Christy Siegel

VP, US Onco Portfolio
GM Women's Health

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2000–2001

Daniel Carreon

Senior Lead Clinical Trial Leader
Translational Clinical Oncology

Pharm.D., Western University of Health Sciences
Fellow 2010–2012

James Lau

Director, Global Field Medical & Scientific Content

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2006-2007

Karli Boniello

Global Program Regulatory Manager
Regulatory Affairs, Immunology

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2020-2022

Kimberly Colligan

Regional Director of MSLs, Field Medical, Immunology

Pharm.D., Albany College of Pharmacy and Health Sciences
Fellow 2009-2011

Moyra Aziz

Associate Director, Launch Scientific Communications, Hematology

Pharm.D., University of Rhode Island
Fellow 2020-2022

Nina Katz

Senior Global Program Regulatory Director Regulatory Affairs, Oncology

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2007–2009

First Year Fellows

Kenny Onate

Global Development
Clinical Development Excellence

M.D., Facultad de Ciencias Medicas de la Universidad Central del Ecuador

Residency in Pediatrics, Sophie Davis School of Medicine

Fellowship in Pediatric Endocrinology, Zucker School of Medicine at Hofstra/Northwell

Madrona Boutros

Global Development
Clinical Development Excellence

Pharm.D., Touro College of Pharmacy

B.S., Biology, College of Staten Island

Meredith Harris

Global Development
Global Program Management

Pharm.D., The Ohio State University

M.S., Translational Pharmacology, The Ohio State University

M.S., Medical Sciences, University of Kentucky

B.S., Biological Sciences, University of Cincinnati

Monica Bennett

Global Development
Early Clinical Development, Translational Clinical Oncology

Pharm.D., University of Florida College of Pharmacy

B.S., Chemistry, Virginia Military Institute

Neelam Patel

Global Development
Pharmacokinetic Sciences

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Sarah Govender

Global Development
Global Clinical Operations

Pharm.D., University of Charleston

B.S., Biochemistry, Marshall University

Chirayu Patel

Medical Affairs
U.S. Publications & U.S. Medical Information

Pharm.D., University of Pittsburgh

B.S., Pharmaceutical Science, University of Pittsburgh

Joseph Kennedy

Medical Affairs
U.S. Field Medical

Pharm.D., University of Rhode Island

Kathryn Hannan

Medical Affairs
Global Scientific Communications

Pharm.D., University of Florida College of Pharmacy

A.A., Liberal Arts and Sciences, University of Florida

Ravi Chothani

Medical Affairs
U.S. Medical Information & Global Field Medical

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

First Year Fellows

Isabel Parzecki

Regulatory Affairs
Regulatory Affairs Strategy
Immunology

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Stephanie Hauser

Regulatory Affairs
Regulatory Affairs Strategy
Oncology

Pharm.D., Wilkes University

"Working and learning from team members across functional areas, while striving towards a shared vision of helping patients, has truly been a rewarding experience."

Second Year Fellows

Karen Nguyen

Commercial
Oncology Brand Management

Pharm.D., University of Maryland School of Pharmacy

B.A., University of Maryland, Baltimore County

Sajida Gowani

Commercial
U.S. Precision Medicine

Pharm.D., Texas Tech University Health Sciences Center

B.S., Neuroscience, University of Texas at Dallas

Osei Agyemang

Global Development
Early Clinical Development, Translational Clinical Oncology

Pharm.D., The University of Tennessee Health Science Center College of Pharmacy

B.S., Pharmaceutical Sciences, University of Tennessee

Alena Stevens

Medical Affairs
Scientific Knowledge Design

Pharm.D., Florida A&M University College of Pharmacy and Pharmaceutical Sciences

Alicia Ademi

Medical Affairs
Gene Therapies

Pharm.D., University of Rhode Island

M.B.A., University of Rhode Island

Harvard Huynh

Medical Affairs
U.S. Field Medical

Pharm.D., St. John's University College of Pharmacy and Health Sciences

Kaela Davis

Medical Affairs
U.S. Medical Information & Global Field Medical Strategy

Pharm.D., Temple University School of Pharmacy

Madison Trauger

Medical Affairs
U.S. Medical Information & Regulatory Advertising & Promotion

Pharm.D., Wilkes University

M.B.A., Wilkes University

B.S., Wilkes University

Chandni Kamdar

Regulatory Affairs
Global Health

Pharm.D., Texas A&M College of Pharmacy

B.S., Biotechnology, University of Houston

Second Year Fellows

Jason Chung

Regulatory Affairs
Neuroscience

Pharm.D., University of Illinois, Chicago

B.S., Biochemistry, University of Illinois, Chicago

Jeremy Jeong

Regulatory Affairs
Early Development

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Lana Zaki

Regulatory Affairs
Global Labeling Strategy

Pharm.D., Long Island University

B.P.S., Pharmaceutical Sciences, Long Island University

Marina Ahmed

Regulatory Affairs
Oncology

Pharm.D., MCPHS University

Third Year Fellow

Sneha Gaitonde

Global Development
Quantitative Safety & Epidemiology

Pharm.D., University of Pittsburgh School of Pharmacy

B.S., Biology, University of North Carolina, Greensboro

"Mentorship, support, and professional growth. These are the words I would use to describe the Novartis Fellowship Program."

2024-2025 Novartis Fellowship Program



Commercial

- *US Precision Medicine*
- US Oncology Marketing Strategy



Global Development

- Clinical Development (Early)
  - Translational Clinical Oncology
  - *PK Sciences*
- Clinical Development (Late-Stage) (PharmD & Physician)
- Global Clinical Operations
- *Global Program Management*
- *Quantitative Safety & Epidemiology*

Medical Affairs

- US Publications/Scientific Knowledge Design & Pub CoE
- US Scientific Knowledge Design
- US Medical Information/ Regulatory Advertising & Promotion
- *Global Scientific Communications*
- *Medical Information/ Field Medical Strategy*

Regulatory Affairs

- RA Global Labeling Strategy
- RA Strategy

Positions located in East Hanover, NJ

Position not recruiting for 2023.

Commercial

The fellow works in cross-functional disease areas or brand teams that drive US Pharma/Oncology strategy and growth. The primary objective is to deliver commercially meaningful brands to the US, providing recommendations to maximize US market opportunities including shaping Phase II and Phase III development programs, optimizing product profiles for successful launch and delivering on brand strategies to drive growth of Novartis promoted products.

Group Leaders

Christy Siegel

VP, U.S. Onco Portfolio
GM Women's Health

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Fellow 2000-2001

Christopher McBurney

Hematology Global TA Head
Global Product Strategy & Capabilities

Pharm.D., University of Toledo

Second Year Fellows

Karen Nguyen

Oncology Brand Management

Sajida Gowani

U.S. Precision Medicine



Commercial

Commercial Fellowship Overview

- Drive development of pipeline products through deliverables including situation analysis, options assessment, patient journey, target product profile, forecast and launch readiness plans.
- Participate in evaluation of business development and licensing opportunities, including scientific/clinical and commercial assessments and participate in due diligence of select opportunities.
- Develop, implement, and execute brand strategy, marketing mix and operational plans that optimize sales, market share and revenue growth for the short and long term.
- Engage with marketing training, field force operations, and field training to enable our brands to achieve their strategic objectives to help patients with access.

"While fellows at Novartis are provided mentorship and resources to be trained within their program's functional area, they are also developed to become well-rounded leaders in pharmaceutical industry as well."

Global Development

Global Development roles oversee the development of new medicines discovered by our researchers and partners. These roles drive breakthrough innovations to improve and extend the lives of patients.

Group Leaders

Brian Manning

Senior Clinical Development Director

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Fellow 2009-2011

Daniel Carreon

Senior Lead Clinical Trial Leader Translational Clinical Oncology

Pharm.D., Western University of Health Sciences

Fellow 2010-2012

Kudsia Hafeez

Global Program Executive Director Cardio-Renal-Metabolic

Pharm.D., Purdue University

Fellow 2001-2003



"A Pharm.D. has the unique skill set to drive drug development from the lab to the patient."

Global Development

Second Year Fellow

Osei Agyemang

Early Clinical Development, Translational Clinical Oncology

Third Year Fellow

Sneha Gaitonde

Quantitative Safety & Epidemiology

First Year Fellows

Kenny Onate

Clinical Development Excellence

Madrona Boutros

Clinical Development Excellence

Meredith Harris

Global Program Management

Monica Bennett

Early Clinical Development, Translational Clinical Oncology

Neelam Patel

Pharmacokinetic Sciences

Sarah Govender

Global Clinical Operations

Global Development

Global Clinical Operations (GCO)

Global Clinical Operations fellows serve as key members of cross-functional clinical trial teams, providing operational input to the study worldwide. In this role, fellows will:

- Support the conduct of global Phase II and III clinical trials and/or Phase IV (e.g., managed access plans, IITs, post-trial access).
- As part of the global Clinical Trial Teams (CTTs):
  - Collaborate with study leadership to ensure goals are met for trial timelines, budget, quality, and operational procedures. Support development of study documents such as protocols, case report forms, and clinical study reports.
  - Interact regularly with other Novartis line functions such as Clinical Development, Biostatistics, Data Management, Medical Writing, Regulatory Affairs, Safety, and Drug Supply.
- Gain hands-on experience in several GCO sub-functions including:
  - Program Strategy & Planning: drive standardized, data-driven, local feasibility, and strengthened clinical trial site selection.
  - Study & Site Operations – Study Start-Up: integrate technology-supported, centralized clinical trial start-up process for faster start-up and decreased cycle time.
  - Vendor Partnerships & Governance: accountable for early vendor strategy, engagement, performance, and oversight.

Global Development

Clinical Development (CD)

Clinical Development teams design innovative patient-friendly clinical development programs to rapidly bring outstanding treatments to patients, caregivers and healthcare systems

In this role, the Late-stage Clinical Development fellow will:

- Work with Clinical Development Director and Medical Director to support the strategic planning and management of assigned programs from an end-to-end perspective
- Provide clinical and strategic input to the development of protocols and regulatory documents
- Be involved with medical and scientific review of clinical trial data with Clinical Scientific Expert(s) with appropriate oversight from Medical Lead
- Support development of study tools, guidelines, and training materials
- Be involved with the design and implementation of the clinical development plan in partnership with the global line functions, Global Clinical Operations, and medical associates

"The Global Development fellowship at Novartis is the perfect balance of structure and flexibility, while also providing mentorship, support and professional growth."

Global Development

Quantitative Safety & Epidemiology (QS&E)

Quantitative Safety & Epidemiology provides high quality scientific contributions to safety management teams to support decision making by providing evidence-based evaluation, understanding, and communication of both safety data and benefit-risk to support decision-making at all stages of the drug life-cycle.

In this global role, the Pharmacoepidemiologist fellow will:

- Learn how to synthesize evidence from published data and how to evaluate, understand, interpret, and communicate patient safety data from diverse sources (e.g., clinical studies, spontaneous reports) but with a focus on real world data.
- Plan, discuss, and execute simple non-interventional studies. Analyses will be used in product submissions, in response to Health Authority questions, in labeling updates, and in regulatory documents, such as Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs).
- Gain the skills needed to conduct pharmacoepidemiologic studies using large, real-world databases. As a part of this training, the fellow will be trained in part by taking classes in PE, study design and statistical analysis. Upon successful completion a certificate in PE will be earned from the Rutgers Center for Pharmacoepidemiology and Treatment Science.
- Utilize his/her analytical skills, previous experience in research training in epidemiology, statistics or related areas, and computing ability, including knowledge of specialized statistical packages (advanced level, SAS or R) to effectively provide support to drug products.

Global Program Management (GPM)

Global Program Management (GPM) drives the strategic planning and execution of drug development programs and provides the information the enterprise needs to make the right portfolio decisions. GPM associates enable the cross-functional Global Program Teams (GPTs) to deliver the pipeline across the research, development, and commercial continuum with optimal strategies, realistic plans, and seamless execution. The GPM fellow will:

- Be assigned a GPT where they will support the team to develop and maintain accurate plans and documentation, ensure smooth day-to-day operations, and help to resolve program issues.
- Be trained in the enterprise project management system and will participate in planning projects, identifying alternative development scenarios, integrating line function activities, challenging schedules, and monitoring implementations.
- Have the opportunity to experience drug development first-hand through the lens of a single program. They will have extensive matrix interactions across a wide range of disciplines with the line function members of the GPT and their colleagues.

Global Development

Early Clinical Development

Translational Medicine

Scientists and clinicians within TM Clinical Sciences & Innovation (TM CS&I) and Translational Clinical Oncology (TCO) are primarily responsible for designing and conducting early phase clinical trials that explore the safety, tolerability and initial assessment of efficacy in healthy volunteers and patients.

- **NIBR TCO:** Fellows will be trained as a Clinical Trial Leader, coordinating all aspects of a clinical trial, which may include: leading a clinical trial team, developing clinical study protocol(s), designing case report forms (CRFs) and informed consent documents, selecting and initiating clinical sites, reviewing safety data, conducting dose escalation meetings, reporting and interpreting study results as well as managing study timelines, drug supply, and study vendors.
- All NIBR Fellows may contribute to program-level activities, including the development of regulatory documents such as the Investigator's Brochure, briefing documents, annual safety reports, regulatory submissions, study abstracts, posters and meeting presentations as opportunities arise.
- Fellows may have the opportunity to support or conduct one or more: first-in-human, proof-of-concept, dose-range finding, PK drug-interaction and/or mechanistic profiling studies for novel therapeutics.

Clinical Pharmacology/PK Sciences

PKS scientists work across the development spectrum and are engaged in the analysis, interpretation and reporting of pharmacokinetic (PK), pharmacodynamic (PD), toxicokinetic (TK) and immunogenicity data generated during discovery through late phase development.

- **NIBR PKS:** Fellows will be trained as a PK Scientist designing studies and analyzing PK/PD data generated across research and full development. Fellows will support project teams and will gain proficiency with key modeling and analysis software platforms, e.g. Phoenix, as well as expertise in clinical pharmacology and PK/TK study design. PKS Fellows will also gain expertise in global regulations guiding clinical pharmacology and biopharmaceutical development.
- Fellows may contribute to planning, writing, and reviewing study designs, data analysis plans, clinical pharmacology study reports, and regulatory documents such as IBs, and INDs.
- The fellow may have the opportunity to gain experience in biologics, first-in-human, drug-drug interactions, food-effect studies, QTc assessment strategies, and special population studies.

Medical Affairs

As part of the Medical Affairs umbrella of disciplines, Scientific Communications, Medical Information, and Field Medical work collaboratively to develop and execute strategic medical communications. Fellowship opportunities in Medical Affairs can include positions in both US and Global functions.

Group Leaders

James Lau

Director, Field Medical & Scientific Content

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Fellow 2006-2007

Kimberly Colligan

Regional Director of MSLs, Field Medical, Immunology

Pharm.D., Albany College of Pharmacy and Health Sciences

Fellow 2009-2011

Moyra Aziz

Associate Director, Launch Scientific Communications, Hematology

Pharm.D., University of Rhode Island

Fellow 2020-2022

"The program at Novartis focuses on building a solid foundation with the goal of making a smooth transition to a successful career after the fellowship."

Medical Affairs

Second Year Fellows

Alena Stevens

Scientific Knowledge Design

Alicia Ademi

Gene Therapies

Harvard Huynh

U.S. Field Medical

Kaela Davis

U.S. Medical Information & Global Field Medical Strategy

Madison Trauger

U.S. Medical Information & Regulatory Advertising & Promotion

First Year Fellows

Chirayu Patel

U.S. Publications & U.S. Medical Information

Joseph Kennedy

U.S. Field Medical

Kathryn Hannan

Global Scientific Communications

Ravi Chothani

U.S. Medical Information & Global Field Medical

Medical Affairs

Individual Fellowship Role Descriptions

Two-year fellowships within Medical Affairs provide an opportunity to learn the fundamental role of a Medical Affairs professional with experience in either a dedicated field medical role or headquarters-based opportunities.

- **Field Medical (MSL)** is responsible for establishing and maintaining relationships with healthcare professionals by engaging in scientific discussions regarding Novartis products, therapeutic areas of interest, and sponsored research. In this role, the fellow will have the opportunity to develop internal medical resources and conduct field medical training for the US field medical team. The fellow will receive medical training curriculum for the defined product(s) and related disease states. During the second year of the program, the fellow will be assigned a territory to engage healthcare professionals in the field.

- The **US Scientific Knowledge Design Lead** is a core member of the US medical strategy team and leads the scientific content creation for external medical communication and education. In this role, the fellow will have the opportunity to develop and execute the medical content creation for: medical science liaison team use, medical conferences, third-party medical education programs, medical websites and social media campaigns. The fellow will be responsible for the accuracy and quality of scientific content.

Medical Affairs

Individual Fellowship Role Descriptions

Fellows in headquarters roles will gain experience translating data on innovative medicines for scientific exchange and can include one or more of the following experiences:

- **Global Scientific Communications** is responsible for developing and disseminating scientific information on Novartis products through publications, medical education, and medical expert management. In this role, the fellow will have the opportunity to develop and execute the global publication plan, medical education curriculum, and driving congress strategy. The fellow will be responsible for the accuracy and quality of scientific content of manuscripts, abstracts, posters and presentations of clinical data. In addition, the fellow will develop internal medical communications and training.

- **MSL Strategy** focuses on developing and executing field medical strategic and tactical plans for scientific exchange. In this role, the fellow will support global MSLs by creating MSL resources (e.g. slide decks, FAQs), scientific communication platforms, internal communications and will lead global MSL team discussions to gather external HCP feedback. The fellow will also be responsible for the medical training curriculum for defined product(s) and related disease states.

- **Medical Information** is responsible for using scientific information to develop medical literature and drug information databases to research, evaluate, and develop evidence-based medical content for countries and regions to manage healthcare professional and customer interactions. The fellow will also be responsible for congress planning including HCP engagement, medical booth staffing and congress debriefs. In this role, the fellow will have the opportunity to develop high quality (relevant, rigorous, balanced) medical information documents for healthcare customers in response to unsolicited inquiries about Novartis products.

- **Regulatory Advertising & Promotion (A&P)** is responsible for ensuring company communications promoting its products are consistent with laws and regulations which govern the promotion of prescription drugs in the US, as well as company policies and procedures related to these activities. In this role, the fellow will learn about the principles which inform US prescription drug promotional rules. The fellow will meet with multi-disciplinary teams who review proposed promotional materials and will have the opportunity to provide regulatory guidance and inform business strategy on non-promotional materials for use by medical affairs associates. In this unique role, the fellow will complete one year in Medical Information and one year in Regulatory A&P.

Regulatory Affairs

Two distinct Regulatory Affairs fellowship opportunities are offered: Regulatory Affairs Strategy and Regulatory Affairs Global Labeling Strategy. In these roles, fellows liaise with global cross-functional teams to provide strategic input to support product development, registration and life cycle maintenance activities.

Group Leaders

Nina Katz

Senior Global Program Regulatory Director
Regulatory Affairs, Oncology

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Fellow 2007-2009



Karli Boniello

Global Program Regulatory Manager
Regulatory Affairs, Immunology

Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Fellow 2020-2022

"From day one, Novartis fellows start to gather responsibilities and work towards being independent leaders and valuable contributors on their respective teams."

Regulatory Affairs

Second Year Fellows

Chandni Kamdar

Regulatory Affairs Strategy
Global Health

Jason Chung

Regulatory Affairs Strategy
Neuroscience

Jeremy Jeong

Regulatory Affairs Strategy
Early Development

Lana Zaki

Regulatory Affairs
Global Labeling Strategy

Marina Ahmed

Regulatory Affairs Strategy
Oncology

First Year Fellows

Isabel Parzecki

Regulatory Affairs Strategy
Immunology

Stephanie Hauser

Regulatory Affairs Strategy
Oncology

Regulatory Affairs

Regulatory Affairs Strategy

- In this role, the fellow will learn to:
  - Conduct regulatory intelligence research and apply regulations and Health Authority guidances to inform global development and registration strategies.
  - Lead global cross-functional teams to implement regulatory strategies.
  - Provide strategic input and tactical support to expedite the development, submission and regulatory approval of new products.
  - Identify and assess regulatory risks and develop mitigation strategies.
  - Support interactions between Novartis and Health Authorities worldwide (e.g., US Food and Drug Administration [US FDA]).
  - Submit and maintain regulatory applications (e.g., Investigational New Drugs [INDs], New Drug Applications [NDAs], Biologics License Applications [BLAs], Clinical Trial Applications [CTAs], Marketing Authorization Applications [MAAs]).

Regulatory Affairs

Regulatory Affairs Global Labeling Strategy

- In this role, the fellow will learn to:
  - Develop labeling strategies by conducting labeling precedent research and applying Health Authority guidances and regulations.
  - Lead global cross-functional teams to develop and maintain regulatory compliant, competitive, and up-to-date global and regional labeling strategies and labeling documents (including the US Prescribing Information [USPI], European Summary of Product Characteristics [EU SmPC], and Novartis company core data sheet).
  - Provide strategic input to develop competitive regional labeling (e.g., USPI) submitted with regulatory applications (e.g., NDAs, BLAs, MAAs).
  - Support negotiations and interactions between Novartis and Health Authorities worldwide (e.g., US FDA) on labeling content.
  - Lead cross-functional support of labeling content related activities worldwide (e.g., authoring of labeling content for regulatory applications, advising on local implementation of labeling changes, and responding to Health Authority comments and requests on labeling content).


At Novartis, we are reimagining medicine

Novartis Fellowship Program Alumni

1990–1992
Mark Ammann
John Gladish

1991–1993
Irene Laurora
Bruce Robbins

1992–1994
Joseph Cordaro

1993–1995
Tracy Acker
Robert Kowalski
Sheri Thornberg

1994–1996
Veronica Valvano Benedetto
Beth Keibler
Taunia Markvicka

1995–1997
Michele Pongowski Ball
John Messina

1996–1998
Latifa Alladina
Branka Kowalski
Patricia Ledford
James Rawls

1997–1999
Soma Gupta
Sausanne Khalilieh
Lisa Kutney
Henry Owunna
Maria Pryor
Katenka Svendsen Schumm

1998–2000
Kelley Piper Bradley
Kimberly Chappell
Lisa Malaty Ghaly
Lisa Pitt
Angela Sansone
Jane Chong Shen
Sheri Dranzo Siegel

1999–2001
Angela Browne
Kay Chitale
Shamita Gupta
Fonda Chen Liu
John Martin
Mendy McGuire
Scott Moren
Maria Moricz
Deepa Patel
Asli (Guven) Santos
Michelle Stolpman Tsai

2000–2002
Bryan Campbell
Bonnie Lieberman
Ariel Mihic
Lillian Ng
Monil Shah
Jennifer (Stolk) Slade
Charlene (So) Hall
Susan Trieu
Andrea Viegas

2001–2003
Kevin Carl
Kimberly Dickerson
Kudsia Hafeez
Angela Liu
Ayanna (Abadie) Osson
Ram Palanki
Gar Park
Rick Satitpunwaycha

2002–2004
Telly Chi
Joseph A. Chiodo III
Darin Curtiss
Vanessa Foti Trainor
Celena Kwong
Laura Hamway
Dat Nguyen
Alan Slade
Stephanie Tallon
Theresa Valdez

2003–2005
Payman Darouian
Harinder Dhillon
Michael Lu
Melissa (Pao) Mitchener
Stephen Mitchener
Todd Phillips
Lincy Thomas George
Lotus Yung

2004–2006
Ira Do
Aaron Huang
Michelle Libner
Erika Massenburg
Felice Peng
Emily Scalise
Bijal Sheth
Lucio Volino

2005–2007
Amena Ali
Chyrin (Buu) Chung
Andy Hwang
Glendolynn Johnson
Amy (Patel) Shah

There is an extensive network of past fellows from Novartis working at the company and across the pharmaceutical industry.

Novartis Fellowship Program Alumni (continued)

2006–2008
Melina Cioffi
Kathy Dong
Vanessa Kan
Suzanne Maahs
Melody M. Lee
Dale Nepert
Leslie Servidio
Chris Sung
Stephanie Whalen

2007–2009
Jonelle Chapman
Nina Gutman Katz
Shilpa Kurpad
John Noh
Kanan Solanki
Myah Tran
Bryan Zembrowski

2008–2010
Shazia Ali
Lyh Ping Lam
Vickie Laurent
Samuel Lee
Christopher Morrison
Dalal Nesheiwat
Hannah Mosca

2009–2011
Mercy Mathew Abraham
Katherine Carter
Brian Manning
Kimberly Mazzarisi Colligan
Bijal Pandhi
Puja (Patel) Geist
Arshdeep Pooni
Jessica Wang

2010–2012
Narin Ahmed
Daniel Carreon
Dannis Chang
Breanne Donohue
Farah N. Hossain
Nickie Gallaher
Drea Pangilinan
Manisha Patel
Jiten Rana
Therese Swan
Alex Wang

2011–2013
Robert Boothroyd
Phillip Koo
Doris Lo
TanTan (Liza) Ng
Demetre Stamatis
Allison Upalawanna

2012–2014
Madhuri Dhawan
Beth Drimalla
Melissa Kuhn
Jeremy Lim
Melissa Neighbors
Joanne Nguyen
Michelle Pernice
Lincoln Rogers
Marilyn Tsourounis

2013–2015
Jenna Konkel
Lisa Krueger
Brigette Nezami
Tuong Vi Nguyen
Hetal Pansuria
Jennifer Poon
Maryam Shirmohamadali
Matt Temer
Iris Wang

2014–2016
Geetha Pudussery
Viraj Degaonkar
Ashley Brower
Naomi Kozlowski
Anisha Baghat
Julia Hautmann
Priya Ramachandran

2015–2017
Kate Bender
Alexandra Hendzel
Rashaad Joseph
Ramya Mathew
Rubin Modi
Zachary Post
Dean Wetty

2016–2018
Jake Myhill
Amanda Bright
Mona Fassihi
Nehali Parikh
Pamela Hill
Gunjan Patel
Galina Perel
Joe Britt
Natalia Ceaicovscaia
Clarice Lee
Sapna Chhagan

2017–2019
Sharon Cross
Austin Ferrara
Nate Fons
Meghan Kelly
Heena Mavani
Shivani Shah

Novartis Fellowship Program Alumni (continued)

2018–2020

Ryan Conway
Sr. Manager, Global Program Regulatory
Novartis

Joe Fink
Associate Director, Clinical Operations
Moderna

Lauren Holmes
Manager, Expert Global Trial
Novartis

Kurtis Lee
Associate Director, Marketing
Novartis

Alan Ross
Senior MSL, Neurology & Immunology
EMD Serono, Inc.

Michael Severo
Associate Director, Scientific Strategy
Global Oncology Marketing
Merck

Victoria Nesbitt
Clinical Trial Leader II, Translational Clinical Oncology
Novartis

Andrew Van Deusen
Manager, Inhaled Products
Honeywell

Akshay Patel
Associate Director, Commercial Regulatory Affairs
Bristol Myers Squibb

Francesca Francois
Senior Manager, Global Scientific Communications, Rare Diseases
Vertex Pharmaceuticals

2019–2021

Jacob Tebbe
Associate Director, US Alzheimer's Disease Marketing
Eli Lilly

Jordan Haines
Associate Director, Global Program Management
Novartis

Daniel Dudman
CORE Manager
Seqirus

Katelyn Schad
Manager, Expert Global Trial
Novartis

Tori Morgan
Manager, Expert Global Trial
Novartis

Jennifer Han
Scientist, Early Clinical Development
Bristol Myers Squibb

Naomey Sarkis Chedid
Associate Director, Early Clinical Development
Bristol Myers Squibb

Christopher Oh
Associate Director, MSL Oncology
Novartis

Cole Cecchini
Senior Manager, Regulatory Affairs
Bristol Myers Squibb

Yasha Patel
MSL, Oncology
Exelixis

Boning Zhao
Sr Manager, Global Regulatory Strategy
Regeneron

Brianna Devitt
Manager, Global Program Regulatory
Novartis

George Shyu
Associated Consultant II
Lumanity

Joanna McCormack
Manager, Global Program Regulatory
Novartis

June Wie
Manager, Global Labeling
Novartis

2020–2022

Jay Shah
Peer-to-Peer Lead, Marketing Strategy
Novartis

Mary Soorial
Product Manager, HCP Marketing
Genmab

Kim Kornbluth
Clinical Trial Leader I, Translational Clinical Oncology
Novartis

Mona Vaidya
Manager, Expert Global Trial
Novartis

Clara Kim
Sr Manager, Oncology Medical Information
Astellas

Dwipi Patel
Sr Manager, Global Scientific Communications
Sarepta Therapeutics

Novartis Fellowship Program Alumni (continued)

2020–2022 (continued)

Frencina Monteiro
Senior Manager, Scientific Knowledge Design Lead
Novartis

Moyra Aziz
Associate Director, Launch Scientific Communications
Novartis

Nicole Coccia
Senior Manager, Commercial Regulatory Affairs
Bristol Myers Squibb

Taylor Todd
Associate Director, MSL
Novartis

Amita Jain
Manager, Global Program Regulatory
Novartis

Farah Elziny
Manager, Global Labeling
Novartis

Joseph Greer
Manager, Global Program Regulatory
Novartis

Karli Boniello
Manager, Global Program Regulatory
Novartis

Sarah Bright
Manager, Global Program Regulatory
Novartis

2021–2023

Courtney Stauffenberg
Associate Director, Portfolio Strategy & Operations
Novartis

Kofi Ansah
Clinical Scientist
IGM Biosciences, Inc.

Krishna Rana
Sr Manager, Clinical Development
Kite Pharma

Jayson Karuna
Manager, Medical Affairs
Fresenius Kabi

Jessica Shue
MSL, Hematology/Oncology
MorphoSys

Radhika Chunduru
Manager, Regulatory Advertising & Promotion Policy
GSK

Shwan Baban
MSL, Rare Hematology
Sanofi

Anna Malik
Senior Scientist, Regulatory Affairs
Merck

Arielle DiPasquale
Manager, Global Program Regulatory
Novartis

Kaileen Musum
Manager, Global Regulatory Affairs
Regeneron

Kelly Ohlinger
Manager, Global Program Regulatory
Novartis

Nicholas Rozelle
Manager, Global Program Regulatory
Novartis

Kristina Royzman
Clinical Operations Program Manager
Novartis

Kathryn Vollmer
Study Leader, Global Clinical Operations
Novartis

Nithya Pothireddy

RUTGERS
Ernest Mario School of Pharmacy

Soaring Ever Higher
Pharmaceutical Industry Fellowship Program

Rutgers Pharmaceutical Industry Fellowship Program

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Program History

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 27 companies within the pharmaceutical and biopharmaceutical industry and approximately 350 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the ***Institute for Pharmaceutical Industry Fellowships*** to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- provide leadership and administrative support
- promote quality, communication, scholarly activity, and professional development
- arrange specialized Fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows' training by adding select physician Fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.

The RPIF Program Certificate is now associated with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**. Well over 1,500 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Connect with us on social media: @RutgersFellow

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers University

Carolyn Seyss, Pharm.D., RUCIF
Fellowship Director
Institute for Pharmaceutical Industry Fellowships
Ernest Mario School of Pharmacy

Michael Toscani, Pharm.D.
Research Professor, Fellowship Director Emeritus
Institute for Pharmaceutical Industry Fellowships
Ernest Mario School of Pharmacy

RUTGERS
Institute for Pharmaceutical Industry Fellowships

RUTGERS
Ernest Mario School of Pharmacy

Soaring Ever Higher
Pharmaceutical Industry Fellowship Program

Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTER**s the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through key program features:

F	**Family of Leading Companies** – Partners include several of the top global pharmaceutical and biopharmaceutical companies and offer large to small company environments.
O	**Outstanding Alumni Track Record** – Well over 1,500 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	**Strong Network** — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	**Trusted and Proven Since 1984** — the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.
E	**Enhanced Career Development** – Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	**Rigorous Academic Component** – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with over 67,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy (EMSOP) is part of Rutgers Biomedical and Health Sciences (RBHS), the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey. Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, the EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Connect with us on social media: @RutgersFellow

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among Fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

RUTGERS
Ernest Mario School of Pharmacy

Soaring Ever Higher
Pharmaceutical Industry Fellowship Program

Application Process and Eligibility Requirements:
Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

How to Apply:
The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as October 6, 2023 by visiting our website at:
https://pharmafellows.rutgers.edu/how-to-apply/

All application materials **must be submitted electronically to the RPIF Website** per instructions on the site.

Your Letter of Intent & Letters of Recommendation should be addressed to:

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

Required Items	Submit by
Application with short-answer questions	October 13th
Letter of Intent (LOI)	October 13th
Curriculum Vitae (CV)	October 13th
Letters of Recommendation (LORs)	December 1st

Alliance of Industry Fellowship Associates Fellowship Offers
Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, AIFA exists to promote a common aspect of each of our program's cultures by supporting a consensus first offer date of December 13, 2023 for all fellowship candidates.

We hope that other academic and non-academic Fellowship Programs will respect this timeline to allow for best program fit for candidates.

AIFA
Alliance of Industry Fellowship Associates

Connect with us on social media: @RutgersFellow

RUTGERS
Institute for Pharmaceutical Industry Fellowships